A randomised controlled trial of telemonitoring and self management in the control of hypertension: Telemonitoring And Self Management IN Hypertension

Conditions

Uncontrolled treated hypertension Circulatory System Hypertension

Hella Muijsers, Olivier W.H. van der Heijden, Karin Boer, Chantal van Bijsterveldt, Ciska Buijs et al. (10 authors)

BMC Women s Health2020-03-049 citations

A Web-Based Self-Titration Program to Control Blood Pressure in Patients With Primary Hypertension: Randomized Controlled Trial

Chi‐Wen Kao, Ting‐Yu Chen, Shu‐Meng Cheng, Wei‐Shiang Lin, Yue‐Cune Chang

Journal of Medical Internet Research2019-10-1925 citations

10.2196/15836

The Stroke Prevention Programme: a programme of research to inform optimal stroke prevention in primary care

Kate Fletcher, Jonathan Mant, Richard J. McManus, Richard Hobbs

Programme Grants for Applied Research2016-03-013 citations

10.3310/pgfar04030

Targets and self-management for the control of blood pressure in stroke and at risk groups (TASMIN-SR): protocol for a randomised controlled trial.

O'Brien C, Bray EP, Bryan S, Greenfield SM, Haque MS, Hobbs FD, Jones MI, Jowett S, Kaambwa B, Little P, Mant J, Penaloza C, Schwartz C, Shackleford H, Varghese J, Williams B, McManus RJ.

2013-03-2314 citations

10.1186/1471-2261-13-21

Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial.

McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, Kaambwa B, Banting M, Bryan S, Little P, Williams B, Hobbs FD.

2010-07-08387 citations

10.1016/s0140-6736(10)60964-6

Interventions

TASMINH2 is a primary-care based, unblinded, randomised controlled trial with embedded economic and qualitative analyses in order to evaluate the costs and effects of increasing patient involvement in

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged between 35 and 75 2. Treated hypertension 3. Blood pressure greater or equal to 140/90 (140/80 mmHg for those with diabetes)

Exclusion criteria

Exclusion criteria: 1. Inability to self monitor 2. More than three antihypertensive medications 3. Terminal disease 4. Blood pressure not managed by their General Practitioner (GP)

Design outcomes

Primary

Measure	Time frame
Mean change in systolic blood pressure (mmHg) between baseline and each follow up point (six months and 12 months), measured in the surgery by the research team.	—

Secondary

Measure	Time frame
1. Adverse events (side effects, anxiety) 2. Health behaviours 3. Patient satisfaction 4. Costs and reasons for non-participation	—

Countries

United Kingdom

Outcome results

None listed